Csenge Advisory Group’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.39M | Buy |
5,327
+1,398
| +36% | +$1.43M | 0.26% | 75 |
|
|
2026
Q1 | $3.61M | Buy |
3,929
+438
| +13% | +$444K | 0.17% | 115 |
|
|
2025
Q4 | $3.75M | Sell |
3,491
-419
| -11% | -$401K | 0.17% | 112 |
|
|
2025
Q3 | $2.98M | Sell |
3,910
-810
| -17% | -$603K | 0.14% | 132 |
|
|
2025
Q2 | $3.48M | Buy |
4,720
+389
| +9% | +$302K | 0.18% | 105 |
|
|
2025
Q1 | $3.64M | Sell |
4,331
-273
| -6% | -$227K | 0.21% | 98 |
|
|
2024
Q4 | $3.55M | Sell |
4,604
-1,370
| -23% | -$1.13M | 0.19% | 102 |
|
|
2024
Q3 | $5.57M | Buy |
5,974
+408
| +7% | +$367K | 0.29% | 69 |
|
|
2024
Q2 | $5.04M | Buy |
5,566
+421
| +8% | +$337K | 0.29% | 67 |
|
|
2024
Q1 | $4M | Buy |
5,145
+933
| +22% | +$664K | 0.22% | 83 |
|
|
2023
Q4 | $2.46M | Buy |
4,212
+73
| +2% | +$42.6K | 0.15% | 119 |
|
|
2023
Q3 | $2.22M | Buy |
4,139
+9
| +0.2% | +$4.64K | 0.15% | 121 |
|
|
2023
Q2 | $1.94M | Buy |
4,130
+669
| +19% | +$281K | 0.13% | 126 |
|
|
2023
Q1 | $1.19M | Sell |
3,461
-14
| -0.4% | -$4.72K | 0.09% | 181 |
|
|
2022
Q4 | $1.27M | Sell |
3,475
-560
| -14% | -$199K | 0.1% | 176 |
|
|
2022
Q3 | $1.3M | Buy |
4,035
+26
| +0.6% | +$8.24K | 0.11% | 168 |
|
|
2022
Q2 | $1.3M | Buy |
4,009
+332
| +9% | +$99.7K | 0.11% | 168 |
|
|
2022
Q1 | $1.05M | Buy |
3,677
+1,002
| +37% | +$258K | 0.08% | 204 |
|
|
2021
Q4 | $618K | Sell |
2,675
-1,655
| -38% | -$420K | 0.06% | 294 |
|
|
2021
Q3 | $994K | Buy |
4,330
+1,655
| +62% | +$408K | 0.08% | 220 |
|
|
2021
Q2 | $618K | Sell |
2,675
-742
| -22% | -$149K | 0.05% | 295 |
|
|
2021
Q1 | $630K | Sell |
3,417
-2,163
| -39% | -$423K | 0.06% | 231 |
|
|
2020
Q4 | $942K | Sell |
5,580
-951
| -15% | -$142K | 0.11% | 138 |
|
|
2020
Q3 | $941K | Buy |
6,531
+333
| +5% | +$51.5K | 0.13% | 132 |
|
|
2020
Q2 | $1.02M | Buy |
6,198
+2,320
| +60% | +$356K | 0.15% | 115 |
|
|
2020
Q1 | $538K | Buy |
3,878
+108
| +3% | +$14.8K | 0.14% | 133 |
|
|
2019
Q4 | $495K | Buy |
3,770
+194
| +5% | +$22.5K | 0.13% | 157 |
|
|
2019
Q3 | $400K | Buy |
+3,576
| New | +$398K | 0.11% | 169 |
|
|
2019
Q1 | – | Sell |
-1,829
| Closed | -$211K | – | 206 |
|
|
2018
Q4 | $211K | Buy |
1,829
+1,300
| +246% | +$145K | 0.08% | 176 |
|
|
2018
Q3 | $58K | Buy |
+529
| New | +$52.9K | 0.02% | 281 |
|
Other funds holding LLY
Csenge Advisory Group's LLY Position: Q2 2026 in Review
Csenge Advisory Group increased its Eli Lilly (LLY) stake by 36% in Q2 2026, buying an estimated $1.43M and bringing the position to 5,327 shares worth $6.39M. The position accounts for 0.26% of the portfolio, ranked #75.
Csenge Advisory Group first reported a position in LLY in Q3 2018 and has held it in 30 quarters since. 4,630 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Csenge Advisory Group held 5,327 shares of Eli Lilly worth $6.39M as of Q2 2026.
- Csenge Advisory Group bought 1,398 Eli Lilly shares in Q2 2026, an estimated $1.43M.
- Eli Lilly made up 0.26% of Csenge Advisory Group's portfolio in Q2 2026, its #75 holding.
- Csenge Advisory Group first reported a position in Eli Lilly in Q3 2018 and has held it in 30 quarters since.
- 4,630 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Csenge Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.